Pan Xinxing, Xu Juan, Jia Xuemei
Department of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu Province, People's Republic of China.
Cancer Manag Res. 2020 Jan 16;12:397-409. doi: 10.2147/CMAR.S232708. eCollection 2020.
Malignant tumors cause a high mortality rate worldwide, and they severely threaten human health and negatively affect the economy. Despite the advancements in tumor-related molecular genetics and effective new processes in anti-tumor drug development, the anti-tumor drugs currently used in clinical practice are inadequate due to their poor efficacy or severe side effects. Therefore, developing new safe and efficient drugs is a top priority for curing cancer. The peptide has become a suitable agent due to its exact molecular weight between whole protein and small molecule, and it has high targeting ability, high penetrability, low immunogenicity, and is convenient to synthesize and easy to modify. Because of these advantages, peptides have excellent prospect for application as anti-tumor agents. This article reviews the recent research progress evaluating anti-tumor peptides and their anti-tumor mechanisms, and may act as a reference for the future development and clinical application of anti-tumor peptides.
恶性肿瘤在全球范围内导致高死亡率,严重威胁人类健康并对经济产生负面影响。尽管肿瘤相关分子遗传学取得了进展,抗肿瘤药物研发也有了有效的新方法,但目前临床实践中使用的抗肿瘤药物由于疗效不佳或副作用严重而存在不足。因此,开发新的安全高效药物是治愈癌症的首要任务。肽因其分子量介于全蛋白和小分子之间而成为一种合适的药物,它具有高靶向性、高渗透性、低免疫原性,且易于合成和修饰。由于这些优点,肽作为抗肿瘤药物具有极好的应用前景。本文综述了评估抗肿瘤肽及其抗肿瘤机制的最新研究进展,可为抗肿瘤肽的未来发展和临床应用提供参考。